MediQuest Therapeutics
Topical therapies for inflammatory and infectious diseases
About MediQuest Therapeutics
MediQuest Therapeutics, Inc. was a specialty biopharmaceutical company that developed therapeutics for treating inflammatory and infectious diseases. Founded in 2002 and based in Seattle, Washington, the company focused on creating treatments based on its proprietary topical amphiMatrix (TAM) drug delivery technology. This system was designed to deliver active agents through thickened skin and nails to the site of inflammation or infection.
The company's pipeline included clinical-stage products targeting conditions such as Raynaud's phenomenon, nail psoriasis, and actinic keratosis. One of its notable projects was MQX-503, a topical formulation for treating Raynaud's Disease, which showed positive results in a Phase III study by reducing symptom severity with minimal side effects. Over its lifetime, MediQuest Therapeutics raised a total of $22 million in funding over four rounds, with investors including Novo Holdings and Janus Henderson Investors. The company, which was also formerly known as Origen Corporation and Oridigm Corporation, is now listed as out of business.
Source: Dealroom company dataNews
Open roles
MediQuest Therapeutics in the Bothell ecosystem
The MediQuest Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Institute of Allergy and Infectious Diseases
Series A6 investors entered at this stage
- IVIntegra Ventures
Novo Seeds
Janus Capital Group
Novo Holdings- MFMasa Life Science Fund
Novo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about MediQuest Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MediQuest Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


